Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients

Publikation: KonferencebidragKonferenceabstrakt til konferenceForskning

Vis graf over relationer
Background and aim: Treatment with antipsychotic drugs is widely associated with metabolic side-effects such as overweight and disturbed glucose metabolism, but the mechanism underlying these side-effects are unclear.
Materials and methods: Fifty-one non-diabetic, antipsychotic-treated male patients ((mean standard deviation) age: 33.1±6.7 years; body mass index (BMI) 26.0±4.7 kg/m2; waist circumference: 95.8±13.2 cm; glycated hemoglobin (HbA1c): 5.7±0.3%) and 93 age and waist circumference-matched healthy male controls (age: 33±7.3 years; BMI: 26.1±3.9 kg/m2; waist circumference: 94.6±11.9 cm; HbA1c: 5.7±0.3%) participated in this cross-sectional study. Blood was sampled in the fasting state and 90 min. after ingestion of a standardized liquid meal (2.268 kJ).
Results: Compared to healthy controls, patients were characterized by elevated fasting levels of glucose, proinsulin, C-peptide and glucose-dependent insulinotropic polypeptide (GIP) and higher postprandial levels of insulin, proinsulin, C-peptide and GIP. Also, patients exhibited elevated plasma levels of C-reactive protein and signs of dyslipidermia. Fasting plasma levels of insulin, glucagon, glucagon-like peptide-1 (GLP-1), ghrelin, leptin, adiponectin, tumor necrosis factor-alpha, plasminogen activator inhibitor, interleukin 6 and postprandial levels of glucagon, GLP-1, ghrelin and adiponectin did not differ between groups.
Conclusion: Presenting with an insulin resistant-like pattern, including beta cell hypersecretion and elevated GIP levels, non-diabetic antipsychotic-treated patients display emerging signs of dysmetabolism and a compromised cardiovascular risk profile. The appetite regulating hormones, GLP-1 and ghrelin appear not to be influenced by antipsychotic treatment. Our findings provide further clinical evidence of the metabolic side-effects of antipsychotics, and put emphasis on the importance of incorporating metabolic screening into psychiatric practice.
Publikationsdatookt. 2014
Antal sider1
StatusUdgivet - okt. 2014
BegivenhedForskningsdag 2014, Glostrup Hospital - Glostrup, Danmark
Varighed: 8 okt. 20148 okt. 2014


KonferenceForskningsdag 2014, Glostrup Hospital


Forskningsdag 2014, Glostrup Hospital


Glostrup, Danmark

Begivenhed: Konference

ID: 44614487